These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32864767)

  • 1. Intracorneal pustular drug eruption associated with nivolumab in a patient with metastatic renal cancer.
    Deinlein T; Kränke B; Cerroni L; Weger W
    Int J Dermatol; 2020 Dec; 59(12):e435-e437. PubMed ID: 32864767
    [No Abstract]   [Full Text] [Related]  

  • 2. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
    Bednarek R; Marks K; Lin G
    Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.
    Ruiz-Bañobre J; Abdulkader I; Anido U; León L; López-López R; García-González J
    APMIS; 2017 Mar; 125(3):259-263. PubMed ID: 28233446
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab-induced lichenoid reaction in a patient with advanced renal cancer.
    Martínez Del Sel J; Benítez N; Allevato M
    Int J Dermatol; 2021 Oct; 60(10):e397-e398. PubMed ID: 34363614
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.
    Vitale MG; Baldessari C; Milella M; Buti S; Militello AM; Di Girolamo S; Fornarini G; Perri G; Basso U; Maruzzo M; Porta C; Cosmai L; Pipitone S; Cerma K; Cascinu S; Sabbatini R
    Clin Genitourin Cancer; 2019 Oct; 17(5):e903-e908. PubMed ID: 31375351
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.
    Beulque Y; Deleu AL; Punie K; De Wever L; Baldewijns M; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Oct; 17(5):e909-e912. PubMed ID: 31378579
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract]   [Full Text] [Related]  

  • 8. Case Report of Akathisia in a Patient With Metastatic Renal Cell Carcinoma on Nivolumab.
    Ho SX; Gass CE; Ruark JM
    J Acad Consult Liaison Psychiatry; 2021; 62(1):119-122. PubMed ID: 33008604
    [No Abstract]   [Full Text] [Related]  

  • 9. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
    Tamada S
    Int J Urol; 2020 Dec; 27(12):1100-1101. PubMed ID: 33006212
    [No Abstract]   [Full Text] [Related]  

  • 11. Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
    Osmán-García I; Congregado-Ruiz CB; Lendínez-Cano G; Baena-Villamarin C; Conde-Sanchez JM; Medina-López RA
    Urol Int; 2020; 104(3-4):323-326. PubMed ID: 31914452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2.
    O'Reilly F; Feldman E; Yang J; Hwu P; Turner ML
    J Am Acad Dermatol; 2003 Apr; 48(4):602-4. PubMed ID: 12664026
    [No Abstract]   [Full Text] [Related]  

  • 13. Nivolumab plus ipilimumab in advanced renal-cell carcinoma.
    Gunjur A
    Lancet Oncol; 2018 May; 19(5):e232. PubMed ID: 29606588
    [No Abstract]   [Full Text] [Related]  

  • 14. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
    Palla AR; Smith E; Doll D
    Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
    Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal damage secondary to check-point inhibitors.
    Moliz C; Cavero T; Morales E; Gutiérrez E; Alonso M; Praga M
    Nefrologia (Engl Ed); 2020; 40(2):206-208. PubMed ID: 31615688
    [No Abstract]   [Full Text] [Related]  

  • 17. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
    Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
    In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
    Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
    Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
    Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
    Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
    Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.